Flavanones (2-phenylchroman-4-ones) are a class of natural product that show extensive biological activities with low toxicity. Compounds with promising activity can be used as leads for synthesis of novel compounds with high efficacy and low side effects to improve drug therapy. Synthetic flavanones have attracted considerable attention because of their various pharmacological properties including antifungal\[[@ref1][@ref2]\], antibacterial\[[@ref1][@ref3][@ref4]\], analgesic\[[@ref4]\], antioxidant\[[@ref4]\], vasorelaxant\[[@ref5]\], AChE inhibitory\[[@ref6]\] and antiVSMCs vegetation\[[@ref7]\] activity. Flavanones have been a potential source in the search for lead compounds so investigation of synthetic routes and chemical modification is a new direction in flavanone research. Flavanones have been reported as a potent anticancer agent\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\] also, but there were very few literature that reported the bioactivity of heteroaryl derivatives, which prompted us to synthesise a novel series of flavanones to investigate the effect by changing the B ring ([fig. 1](#F1){ref-type="fig"}) to a heterocycle ring on *in vitro* anticancer activity. We herein, report the synthesis and evaluation of flavanones. The first step was Claisen--Schmidt reaction between heterocyclic benzaldehyde and 2-hydroxy acetophenone to form 2-hydroxy chalcone derivatives, which on intramolecular addition reaction, gave flavanone derivatives as shown in [Scheme 1](#F2){ref-type="fig"}. The structures of target compounds are described in [Scheme 2](#F3){ref-type="fig"}.

![Flavanone (2-phenylchroman-4-one).](IJPhS-76-163-g001){#F1}

![Synthesis of flavanone derivatives.](IJPhS-76-163-g002){#F2}

![Target compounds.](IJPhS-76-163-g003){#F3}

All the chemicals used for the synthesis of the compounds were obtained from Merck Ltd., Mumbai and SD Fine-Chem Ltd. Mumbai. Melting points were determined in open capillaries and are uncorrected. The compounds were analysed for elemental analysis. IR spectra were recorded on an FTIR spectrometer (Perkin Elmer) using KBr disc method. ^1^H NMR spectra were recorded on ^1^H NMR (Brucker AMx300 MHz) spectrometer in CDCl~3~.

General procedure for the synthesis of title compounds used was as follows: a mixture of the 2-hydroxy acetophenone (0.01 mol, 1.36 g) and corresponding heterocyclic aldehyde (0.01 mol) was taken in ethanol (30 ml) and stirred at 10-15°. To this solution, an aqueous solution of sodium hydroxide (40%, 5.0 ml) was added drop wise with continuous stirring. The mixture was kept overnight at room temperature and then it was poured into crushed ice and acidified with diluted hydrochloric acid. The chalcone precipitated as solid. The precipitated chalcone was collected and recrystallised from ethanol.

The synthesised chalcones (0.1 mmol) and sodium acetate (163 mg, 1.99 mmol) was added to a solution of ethyl alcohol (2.2 ml) and water (0.8 ml), the mixture was heated to reflux for 24 h, the solvent was evaporated under vacuum, 10 ml water was added to the residue and extracted with ethyl acetate (10 ml×3), the combined organic layer was washed with 2 N sodium hydroxide (brine), and dried over anhydrous sodium sulphate. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (petroleum ether:EtOAc; 4:1) to afford compounds YP-1 to YP-6. The purity of the synthesised compounds was established by TLC and melting point. The physical data of the compounds is listed in [Table 1](#T1){ref-type="table"}. The structures of the synthesised compounds YP-1 to YP-6 were characterised by IR and ^1^H NMR and the spectral data are summarised below.

###### 

PHYSICAL CHARACTERISATION DATA OF SYNTHESISED FLAVANONES (YP-1 TO YP-6)
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Compound YP-1; FTIR (KBr, cm^-1^): 3010 (Ar=C-H str.), 1646 (C=O str.), 1589 (C-C str.), 1516, 1462, 1419 (Ar C=C str.), 1193 (C-O-C str.); ^1^H NMR (CDCl~3~, δ ppm): 3.43, 3.17 (d, 2H, methylene), 5.54 (t, 1H, methine), 5.88 (s, 2H, methylene dioxy), 6.54--7.80 (m, 7H, Ar-H). Compound YP-2; FTIR (KBr, cm^-1^): 3014 (Ar=C-H str.), 1686 (C=O str.), 1581 (C-C str.), 1519, 1460, 1415 (Ar C=C str.), 1239 (C-N str.), 1190 (C-O-C str.); ^1^H NMR (CDCl~3~, δ ppm): 2.35 (m, 4H, morpholine), 3.15, 2.93 (d, 2H, methylene), 3.65 (m, 4H, morpholine), 5.35 (t, 1H, methine), 6.83--7.53 (m, 4H, Ar-H).

Compound YP-3; FTIR (KBr, cm^-1^): 3065 (Ar=C-H str.), 1658 (C=O str.), 1600 (C-C str.), 1540 (C=N str.), 1559, 1458, 1420 (Ar C=C str.), 1196 (C-O-C str.); ^1^H NMR (CDCl~3~, δ ppm): 3.17, 2.90 (d, 2H, methylene), 5.52 (t, 1H, methine), 6.90-8.61 (m, 8H, Ar-H). Compound YP-4; FTIR (KBr, cm^-1^): 3012 (Ar=C-H str.), 1667 (C=O str.), 1598 (C-C str.), 1567, 1485, 1443 (Ar C=C str.), 1178 (C-O-C str.); ^1^H NMR (CDCl~3~, δ ppm): 3.18, 3.13, (d, 2H, methylene), 5.49 (t, 1H, methine), 6.19--7.38 (m, 7H, Ar-H).

Compound YP-5; FTIR (KBr, cm^-1^): 3117 (Ar=C-H str.), 1670 (C=O str.), 1612 (C-C str.), 1576, 1456, 1426 (Ar C=C str.), 1242 (C-N str.), 1167 (C-O-C str.); ^1^H NMR (CDCl~3~, δ ppm): 3.33, 3.09 (d, 2H, methylene), 5.10 (d, 1H, pyrrole N-H), 5.13 (t, 1H, methine), 5.72--6.36 (m, 3H, pyrrole), 6.90-7.75 (m, 4H, Ar-H). Compound YP-6; FTIR (KBr, cm^-1^): 3038 (Ar=C-H str.), 2846 (C-H str.), 1669 (C=O str.), 1587 (C-C str.), 1553, 1460, 1432 (Ar C=C str.), 1117 (C-O-C str.), 644 (C-S str.); ^1^H NMR (CDCl~3~, δ ppm): 3.38, 3.13 (d, 2H, methylene), 5.51 (t, 1H, methine), 6.62--7.79 (m, 7H, Ar-H).

The *in vitro* anticancer activity of synthesised flavanones was tested against human mammary adenocarcinoma (MCF7), human colon adenocarcinoma (HT29) and human kidney adenocarcinoma (A498) using sulforhodamine B dye\[[@ref15]\]. 2-Phenyl chroman-4-one, a kind of flavanone, was tested together as a positive control in the assay. The *in vitro* anticancer activity results are summarised in [Table 2](#T2){ref-type="table"}. In accordance with the data from *in vitro* anticancer activity, all the synthesised heteroaryl flavanone derivatives have shown mild to good activity compared with that of positive control 2-phenyl chroman-4-one. The activity data indicate that the compound YP-4 with furan ring (B ring) had the strongest activity against MCF7, HT29 and A498 with IC~50~ values of 7.3, 4.9 and 5.7 μg/ml, respectively.
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*IN VITRO* ANTICANCER ACTIVITY OF SYNTHESISED FLAVANONES *YP-1* TO *YP-6*
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In conclusion, a few number of new heterocycle containing flavanone derivatives were synthesised and studied for *in vitro* anticancer activity, and a furan ring containing analogue YP-4 had highest anticancer potency compared with those of other flavanones. These results suggested that furan ring may be crucial for anticancer activity and contribute to further understanding the critical molecular requirements that lead to anticancer property in the flavanones series. On the basis of the above findings, these flavanones scaffolds can be selected as skeleton for the development of heterocycle containing flavanones with potential as anticancer drugs.
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